AR133167A1 - Macrociclos para el tratamiento de enfermedad autoinmunitaria - Google Patents
Macrociclos para el tratamiento de enfermedad autoinmunitariaInfo
- Publication number
- AR133167A1 AR133167A1 ARP240101740A ARP240101740A AR133167A1 AR 133167 A1 AR133167 A1 AR 133167A1 AR P240101740 A ARP240101740 A AR P240101740A AR P240101740 A ARP240101740 A AR P240101740A AR 133167 A1 AR133167 A1 AR 133167A1
- Authority
- AR
- Argentina
- Prior art keywords
- macrocycles
- treatment
- autoimmune disease
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (I-2), en los que R¹ a R³, Q¹, Q², A¹ a A⁷ y M¹ son como se describe en el presente documento, y la sal farmacéuticamente aceptable de los mismos, y composiciones que incluyen los compuestos y los procedimientos de uso de los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023106401 | 2023-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133167A1 true AR133167A1 (es) | 2025-09-03 |
Family
ID=91898258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101740A AR133167A1 (es) | 2023-07-07 | 2024-07-04 | Macrociclos para el tratamiento de enfermedad autoinmunitaria |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4739670A1 (es) |
| JP (1) | JP2026522985A (es) |
| CN (1) | CN121443595A (es) |
| AR (1) | AR133167A1 (es) |
| TW (1) | TW202517653A (es) |
| WO (1) | WO2025012057A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120904077A (zh) * | 2025-09-30 | 2025-11-07 | 安徽泽升科技股份有限公司 | 一种苯肼盐酸盐的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| CN110386944B (zh) * | 2018-04-16 | 2021-10-29 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
| DK4004002T3 (da) * | 2019-07-22 | 2024-09-30 | Lupin Ltd | Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed |
| JP2025519430A (ja) * | 2022-06-06 | 2025-06-26 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのインダゾール大環状分子 |
-
2024
- 2024-07-04 AR ARP240101740A patent/AR133167A1/es unknown
- 2024-07-04 WO PCT/EP2024/068795 patent/WO2025012057A1/en not_active Ceased
- 2024-07-04 EP EP24740377.7A patent/EP4739670A1/en active Pending
- 2024-07-04 JP JP2026500289A patent/JP2026522985A/ja active Pending
- 2024-07-04 CN CN202480045851.XA patent/CN121443595A/zh active Pending
- 2024-07-05 TW TW113125220A patent/TW202517653A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025012057A1 (en) | 2025-01-16 |
| TW202517653A (zh) | 2025-05-01 |
| EP4739670A1 (en) | 2026-05-13 |
| JP2026522985A (ja) | 2026-07-09 |
| CN121443595A (zh) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2025001184A2 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CL2024004085A1 (es) | Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer. | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CO2026002343A2 (es) | Inhibidores de pi3k | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| UY38057A (es) | Inhibidores de sarcómero cardíaco | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| PY2132400A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| CO2025011377A2 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| CL2025000161A1 (es) | Compuestos cíclicos y métodos de utilización de estos. | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| EA202091481A1 (ru) | Замещенные алкиниленовые соединения в качестве противораковых агентов | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| CL2024000791A1 (es) | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias | |
| ECSP088237A (es) | Derivados de quinolina y uso como agentes antitumor | |
| AR133915A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| AR131849A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer |